Back to top
more

Avanos Medical (AVNS)

(Delayed Data from NYSE)

$24.00 USD

24.00
153,331

+0.46 (1.95%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $23.99 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.

What's in Store for Cardinal Health (CAH) in Q1 Earnings?

by Zacks Equity Research

Cardinal Health's (CAH) first-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical segment.

Why Avanos (AVNS) Might Surprise This Earnings Season

by Zacks Equity Research

Avanos (AVNS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Stryker (SYK) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Stryker's (SYK) third-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

Cencora (COR) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Cencora's (COR) fiscal fourth-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) third-quarter 2023 results are likely to reflect a recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Baxter's (BAX) third-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) second-quarter fiscal 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.

Revvity (RVTY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Revvity's (RVTY) third-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.

Avanos Medical (AVNS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Avanos Medical (AVNS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DexCom (DXCM) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

DexCom's (DXCM) third-quarter 2023 results are likely to reflect rising volumes across all channels.

Avanos (AVNS) Q2 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall second-quarter results reflect soft performances.

Avanos Medical (AVNS) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of -29.41% and 12.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter 2023 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued hurting margins.

AVNS vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

AVNS vs. EW: Which Stock Is the Better Value Option?

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter 2023 results are likely to reflect rising volumes across all channels.

Baxter (BAX) to Post Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Baxter's (BAX) second-quarter results are likely to reflect growth in elective surgical procedures, offset by currency movement. Hillrom's products might have boosted sales.

Intuitive Surgical (ISRG) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.

Avanos' (AVNS) Latest Buyout to Boost Its RF Product Offering

by Zacks Equity Research

Avanos' (AVNS) latest acquisition is expected to strengthen its foothold with a comprehensive suite of RF offerings.

Masimo (MASI) Down 6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Avanos (AVNS) Q1 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Chronic Care segment, its overall first-quarter results reflect soft performances.

Here's Why You Should Retain Exact Sciences (EXAS) Stock Now

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.

Avanos Medical (AVNS) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Avanos Medical (AVNS) delivered earnings and revenue surprises of -3.57% and 1.54%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

National Vision's (EYE) share price is likely to grow following the company's efforts to expand remote capabilities and investments in doctor recruiting and retention efforts.